Advances in molecular pathology and therapy of non-small cell lung cancer
Abstract Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifyin...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-06-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-025-02243-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221728834256896 |
|---|---|
| author | Qing Huang Yuanxiang Li Yingdan Huang Jingyi Wu Wendai Bao Chang Xue Xiaoyu Li Shuang Dong Zhiqiang Dong Sheng Hu |
| author_facet | Qing Huang Yuanxiang Li Yingdan Huang Jingyi Wu Wendai Bao Chang Xue Xiaoyu Li Shuang Dong Zhiqiang Dong Sheng Hu |
| author_sort | Qing Huang |
| collection | DOAJ |
| description | Abstract Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifying the breadth and depth of the therapeutic effect requires comprehending and integrating diverse and profound progress. In this review, therefore, we aim to comprehensively present such progress that spans the various aspects of molecular pathology, encompassing elucidations of metastatic mechanisms, identification of therapeutic targets, and dissection of spatial omics. Additionally, we also highlight the numerous small molecule and antibody drugs, encompassing their application alone or in combination, across later-line, frontline, neoadjuvant or adjuvant settings. Then, we elaborate on drug resistance mechanisms, mainly involving targeted therapies and immunotherapies, revealed by our proposed theoretical models to clarify interactions between cancer cells and a variety of non-malignant cells, as well as almost all the biological regulatory pathways. Finally, we outline mechanistic perspectives to pursue innovative treatments of NSCLC, through leveraging artificial intelligence to incorporate the latest insights into the design of finely-tuned, biomarker-driven combination strategies. This review not only provides an overview of the various strategies of how to reshape available armamentarium, but also illustrates an example of clinical translation of how to develop novel targeted drugs, to revolutionize therapeutic landscape for NSCLC. |
| format | Article |
| id | doaj-art-eb3062e152aa4f14971c67d8b1e4b816 |
| institution | OA Journals |
| issn | 2059-3635 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj-art-eb3062e152aa4f14971c67d8b1e4b8162025-08-20T02:06:36ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352025-06-0110117210.1038/s41392-025-02243-6Advances in molecular pathology and therapy of non-small cell lung cancerQing Huang0Yuanxiang Li1Yingdan Huang2Jingyi Wu3Wendai Bao4Chang Xue5Xiaoyu Li6Shuang Dong7Zhiqiang Dong8Sheng Hu9Department of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalCenter for Neurological Disease Research, Taihe Hospital, Hubei University of MedicineDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalDepartment of Medical Oncology, Huazhong University of Science and Technology, Tongji Medical College, Hubei Cancer HospitalAbstract Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifying the breadth and depth of the therapeutic effect requires comprehending and integrating diverse and profound progress. In this review, therefore, we aim to comprehensively present such progress that spans the various aspects of molecular pathology, encompassing elucidations of metastatic mechanisms, identification of therapeutic targets, and dissection of spatial omics. Additionally, we also highlight the numerous small molecule and antibody drugs, encompassing their application alone or in combination, across later-line, frontline, neoadjuvant or adjuvant settings. Then, we elaborate on drug resistance mechanisms, mainly involving targeted therapies and immunotherapies, revealed by our proposed theoretical models to clarify interactions between cancer cells and a variety of non-malignant cells, as well as almost all the biological regulatory pathways. Finally, we outline mechanistic perspectives to pursue innovative treatments of NSCLC, through leveraging artificial intelligence to incorporate the latest insights into the design of finely-tuned, biomarker-driven combination strategies. This review not only provides an overview of the various strategies of how to reshape available armamentarium, but also illustrates an example of clinical translation of how to develop novel targeted drugs, to revolutionize therapeutic landscape for NSCLC.https://doi.org/10.1038/s41392-025-02243-6 |
| spellingShingle | Qing Huang Yuanxiang Li Yingdan Huang Jingyi Wu Wendai Bao Chang Xue Xiaoyu Li Shuang Dong Zhiqiang Dong Sheng Hu Advances in molecular pathology and therapy of non-small cell lung cancer Signal Transduction and Targeted Therapy |
| title | Advances in molecular pathology and therapy of non-small cell lung cancer |
| title_full | Advances in molecular pathology and therapy of non-small cell lung cancer |
| title_fullStr | Advances in molecular pathology and therapy of non-small cell lung cancer |
| title_full_unstemmed | Advances in molecular pathology and therapy of non-small cell lung cancer |
| title_short | Advances in molecular pathology and therapy of non-small cell lung cancer |
| title_sort | advances in molecular pathology and therapy of non small cell lung cancer |
| url | https://doi.org/10.1038/s41392-025-02243-6 |
| work_keys_str_mv | AT qinghuang advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT yuanxiangli advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT yingdanhuang advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT jingyiwu advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT wendaibao advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT changxue advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT xiaoyuli advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT shuangdong advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT zhiqiangdong advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer AT shenghu advancesinmolecularpathologyandtherapyofnonsmallcelllungcancer |